New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical companies have the most drug patents in Finland?

This chart shows the pharmaceutical companies with the most patents in Finland.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

For a global perspective, see the Drug companies with the greatest global patent coverage.

The companies with the greatest patent coverage in Finland are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in Bulgaria?

This chart shows the drugs with the most patents in Bulgaria.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in Bulgaria are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Glaxosmithkline drug TRELEGY ELLIPTA

Annual Drug Patent Expirations for TRELEGY+ELLIPTA
Annual Drug Patent Expirations for TRELEGY+ELLIPTA

Trelegy Ellipta is a drug marketed by Glaxosmithkline
and is included in one NDA. It is available from one supplier.

The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Optnose Us drug XHANCE

Annual Drug Patent Expirations for XHANCE
Annual Drug Patent Expirations for XHANCE

Xhance is a drug marketed by Optnose Us
and is included in one NDA. It is available from one supplier.

The generic ingredient in XHANCE is fluticasone propionate. One supplier is listed for this compound. Additional details are available on the fluticasone propionate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Promius Pharma drug SERNIVO

Annual Drug Patent Expirations for SERNIVO
Annual Drug Patent Expirations for SERNIVO

Sernivo is a drug marketed by Promius Pharma Llc
and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

This drug has five patent family members in four countries.

The generic ingredient in SERNIVO is betamethasone dipropionate. One supplier is listed for this compound. Additional details are available on the betamethasone dipropionate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent for Hoffmann La drug VALCYTE

Annual Drug Patent Expirations for VALCYTE
Annual Drug Patent Expirations for VALCYTE

Valcyte is a drug marketed by Hoffmann La Roche
and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has thirty-two patent family members in thirty countries.

The generic ingredient in VALCYTE is valganciclovir hydrochloride. One supplier is listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New tentative approval for Watson Labs drug dienogest; estradiol valerate

Dienogest; estradiol valerate is the generic ingredient in one branded drug marketed by Bayer Hlthcare
and is included in one NDA. There are four patents protecting this compound.

This ingredient has ninety-four patent family members in forty-three countries.

Three suppliers are listed for this compound. There is one tentative approval for this compound.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in Brazil?

This chart shows the drugs with the most patents in Brazil.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in Brazil are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com